Pharmaceuticals, Biotechnology & Life Sciences

Insider buying at Thermo Fisher Scientific signals confidence in its mid‑growth outlook, boosting investor sentiment.

Thermo Fisher CFO’s 1,534‑share buy signals management’s confidence and a potential short‑term upside amid dividend hikes and positive market sentiment.

Prime Medicine insider buys signal CEO confidence in a big biotech win – 1.3 M stock options, rising share price, and growing market sentiment show a promising next phase.

CEO insider sell‑off sparks debate on UniQure’s gene‑therapy outlook, raising questions about management confidence amid strong market gains.

Inovio insider moves reveal a liquidity‑focused strategy: chief scientific officer Humeau Laurent buys and sells RSUs, hinting at short‑term cash needs while still backing the company’s vaccine pipeline.

Insider buying surge at Myriad signals confidence amid volatility: 104,000+ shares purchased, potential upside, and strategic pipeline insights.

UroGen insider buying signals optimism amid strong clinical data: insider purchases, positive sentiment, and upcoming conference highlight potential upside, but investors should watch regulatory risks.

Insider buy of VeraDermics shares at $17 signals confidence ahead of Phase 3 results; 1 % stake may hint at undervaluation and potential upside.

Alkermes insider trading shows mixed buying and selling, suggesting leadership confidence amid earnings volatility and a potential rebound in the biopharma’s CNS pipeline.

Plus Therapeutics CFO Andrew MacIntyre buys 349,542 RSUs & options, signaling confidence amid a $0.28 share price, potential reimbursement boost, and volatile outlook.